Canada’s Aurinia Pharmaceuticals is one step closer to releasing voclosporin — a new drug now being developed to treat active lupus nephritis (LN). In a press release, Aurinia announced plans for a Phase 3 clinical trial (AURORA; NCT03021499). Along with ongoing discussions with both the European Medicines Agency (EMA) and Japan’s…
News
Infants with neonatal lupus syndrome can have autoantibodies that fight other autoantibodies. In this case, the autoantibodies doing the targeting are fighting SSA/Ro autoantibodies associated with the development of autoimmune diseases. Now researchers have discovered that most infants with neonatal lupus syndrome who have the autoantibodies that fight SSA/Ro develop mild…
Nearly 300 leaders in the New York fashion, entertainment and entertainment world gathered at the Plaza Hotel on April 4 for the 8th Annual Lupus Handbag Luncheon & Silent Auction. The event — the first hosted by the newly formed Lupus Research Alliance — raised an unspecified amount of money for lupus…
A therapy that XTL Biopharmaceuticals is developing for autoimmune diseases significantly reduced the expression of several cell signaling molecules called cytokines that play a role in the development of Sjögren’s syndrome (SS) associated with lupus, the company reported. The news came in a press release updating XTL’s efforts to develop hCDR1 for systemic…
New research from Switzerland reported that disease activity in patients with systemic lupus erythematosus (SLE) has a negative impact on the quality of life of these patients. The study, titled “Impact of disease activity on health-related quality of life in systemic lupus erythematosus — a cross-sectional analysis of the Swiss Systemic…
Results from the Phase 2 BUTTERFLY trial conducted by Pfizer suggest that an antibody against the pro-inflammatory cytokine interleukin-6 (IL-6) may be a promising treatment for systemic lupus erythematosus (SLE). The study, “Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II…
The Lupus Research Alliance has chosen its Novel Research Grant Class of 2017, which consists of 10 projects that represent innovative approaches in lupus-treatment development. “Standing on a 16-year foundation of documented success, the Novel Research Grants bring new insight and untried directions to the complexities of lupus,” Margaret Dowd, the…
People who have systemic lupus erythematosus (SLE) are more likely to suffer from periodontitis than those without the disease, a new study says. The study, “Subgingival microbiota dysbiosis in systemic lupus erythematosus: association with periodontal status,” appeared in the journal Microbiome. Periodontitis, an infectious disease that affects tissues supporting the…
Nektar Therapeutics dosed the first patient in its Phase 1 clinical trial evaluating NKTR-358 as a treatment for inflammatory and autoimmune disorders such as lupus. NKTR-358 is designed to correct the underlying immune system dysfunction shared by several autoimmune diseases. The drug candidate selectively stimulates the growth and activation of…
Canada’s Aurinia Pharmaceuticals says its experimental immunosuppressant drug voclosporin has shown promise in treating lupus nephritis (LN). Results of the recent AURION clinical trial also showed that certain biomarkers may help predict patients’ response to treatment with voclosporin. Robert Huizinga, Aurinia’s vice-president of clinical affairs, presented the findings at the 12th…
Recent Posts
- To my ‘forever nurse,’ who finally gave me my diagnosis of lupus
- New analyses show Benlysta may aid flare control, kidney health
- Can art therapy help lupus patients improve cognitive function?
- With chronic illness, checking in means asking, ‘How ya really doin’?’
- FDA approves Gazyva as lupus nephritis treatment